Loading
RadNet, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 13 Aug 2021.
RadNet, Inc.: what insiders have been doing
RadNet, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Between 18 October 2025 and 18 October 2026, 13 insiders published 27 filings.
The flow runs one way only: 5 sales worth €4.3M, from 3 insiders, and no purchase. The amount is not disclosed for 2 filings. One trade stands out by size: a sale of €2.1M from Forthuber Stephen M, disclosed on 9 December 2025.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Compared with its exchange (5,816 companies, median 19 filings), a count of 27 filings is above the norm. Since 2016, the database holds 2 purchases and 58 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 2.04 bn USD and net income at -18.7 m USD.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
206
Thresholds
n/a
Buy Volume
€262,138
2 ops. · all time
Sell Volume
€40M
58 ops. · all time
Who traded when
BuySaleCornelis Wesdorp4 sales
Alma Gregory Sorensen3 sales
David Jeffrey Katz3 sales
Norman R. Hames3 sales
Stephen M. Forthuber3 sales
Jayanathan Ranjan2 sales
+5 other insiders
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,785 of 24,148 companies
25.9
score / 100
Value31
Quality20
FCF yld1.5%
Earn yld-0.3%
EV/EBITDA23.9x
ROE1.5%
Gross mgn12%
Net mgn-0.9%
Debt/EBITDA5.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$71.51
Analyst consensus
8 analysts1.25/5
US$79.00Target US$94.63(+32%)US$105.00
Income statement
RevenueUS$2B
Gross profitUS$235.5M12% margin
EBITDAUS$313.8M15% margin
Net income-US$18.7M-0.9% margin
Valuation
PER (forward)80.7x
P/Book5.1x
Beta1.41
Balance sheet & cash
Market capUS$5.6B
Total debtUS$1.9B
Free Cash FlowUS$85.6M
Debt / Equity157%
Profitability & ownership
ROE1.5%
ROA1.7%
% insiders10.0%
% institutions105.6%
Last declaration on 18 June 2026
Declarations206 total
2,699 shares@ US$53.89010.0028% mcap100.0% of flowCommonSEC144:0001950047-26-006335
90 sharesCommon StockSEC:0001683168-26-004991:0
4,750 shares@ US$56.710.0051% mcap100.0% of flowCommonSEC144:0001683168-26-004877
24,214 sharesCommon StockSEC:0001683168-26-004874:0
19,853 sharesCommon StockSEC:0001683168-26-004874:1
44,067 shares@ US$58.15730.049% mcap100.0% of flowCommonSEC144:0001950047-26-006106
9,554 shares@ US$61.848.4% of flowCommon StockSEC:0001683168-26-002116:0
5,919 shares@ US$61.725.2% of flowCommon StockSEC:0001683168-26-001992:0
3,742 shares0Common StockSEC:0001683168-26-001742:0
20,330 shares0Common StockSEC:0001683168-26-001531:0
22,045 shares0Common StockSEC:0001683168-26-001528:0
124,001 shares0Common StockSEC:0001683168-26-001527:0
22,045 shares0Common StockSEC:0001683168-26-001526:0
6,613 shares0Common StockSEC:0001683168-26-001525:0
16,533 shares0Common StockSEC:0001683168-26-001524:0
19,289 shares0Common StockSEC:0001683168-26-001532:0
20,667 shares0Common StockSEC:0001683168-26-001530:0
18,228 shares0Common StockSEC:0001683168-26-001529:0
3,396 shares@ US$29.442.3% of flowCommon StockSEC:0001683168-25-009106:0
35,703 shares@ US$6.074.9% of flowCommon StockSEC:0001683168-25-009105:0
31,790 shares@ US$77.9943.8% of flowCommon StockSEC:0001683168-25-009020:0
630 shares0Common StockSEC:0001683168-25-008907:0
39,127 shares@ US$6.074.2% of flowCommon StockSEC:0001683168-25-008822:0
2,700 shares0Common StockSEC:0001683168-25-008724:0
103,969 shares@ US$18.64100.0% of flowCommon StockSEC:0001683168-25-008616:0
25 of 206 declarations
About RadNet, Inc.
RadNet, Inc. is a U.S.-based leader in outpatient diagnostic imaging. The company is listed on NASDAQ in the United States under the ticker RDNT. Its business model combines a large network of fixed-site imaging centers with radiology services and, increasingly, a digital health platform. According to company disclosures, RadNet was founded in 1984 by a group of physicians and has evolved into a scaled national platform built around access, clinical quality, and operating efficiency. ([radnet.com](https://www.radnet.com/corp/about-radnet?utm_source=openai))
RadNet’s core operations include outpatient diagnostic services such as MRI, CT, X-ray, ultrasound, 3D mammography, and other imaging modalities. The company also emphasizes clinical and technology-enabled support services for referring physicians, hospitals, and payers. Its geographic footprint is entirely U.S.-based, with regional networks across major markets including California, New York, New Jersey, Delaware, Maryland, and Florida. RadNet describes itself as the largest national provider of freestanding outpatient imaging services by number of locations, with a sizable center network and more than 10 million outpatient procedures annually. ([radnet.com](https://www.radnet.com/corp/about-radnet?utm_source=openai))
Read moreShow less
From a competitive standpoint, RadNet’s appeal lies in scale, dense local coverage, and the ability to provide a multi-modality “one-stop shop” for referring physicians and health plans. That footprint supports negotiating leverage, patient convenience, and operational efficiency. The company also highlights its technology positioning, including radiology software capabilities and a growing digital health segment, which is becoming increasingly important as imaging workflows become more data-driven and integrated across care settings. ([radnet.com](https://www.radnet.com/corp/about-radnet?utm_source=openai))
Recent developments reinforce that strategy. RadNet reported record fourth-quarter 2025 revenue of $547.7 million and continued strong growth in its Digital Health segment. In the first quarter of 2026, management said the business rebounded after severe winter weather in the U.S. Northeast and raised its 2026 guidance for the imaging center business. For investors, RadNet is best viewed as a healthcare franchise listed on NASDAQ in the United States, with a defensive end-market and an additional growth vector tied to digitalization, workflow automation, and imaging network optimization. ([radnet.com](https://www.radnet.com/about-radnet/news/radnet-reports-fourth-quarter-2025-results-including-record-revenue-and-adjusted-ebitda-and-releases-2026-financial-guidance?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
